The ability to target either GRPR or αvβ3 biomarkers simultaneously via a heterodimeric targeting ligand has provided a new avenue to investigate the dual targeting capacity of bivalent radioligands for improved in vivo PET images of specific human cancers. The gene discussed is GRPR; the disease is cancer.